<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ceftibuten</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01415</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent. Cefalexin is used to treat acute bacterial exacerbations of chronic bronchitis (<span class="caps">ABECB</span>), acute bacterial otitis media, pharyngitis, and tonsilitis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01415/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01415/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01415.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01415.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01415.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01415.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01415.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01415">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cedax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/cephalosporins">Cephalosporins</a></li></ul></td></tr><tr><th>CAS number</th><td>97519-39-6</td></tr><tr><th>Weight</th><td>Average: 410.425<br>Monoisotopic: 410.03547558</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O<sub>6</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>UNJFKXSSGBWRBZ-BJCIPQKHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Cephalosporins</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; 2,4-disubstituted Thiazoles; Aminothiazoles; Dicarboxylic Acids and Derivatives; Primary Aromatic Amines; 1,3-Thiazines; Enones; Tertiary Carboxylic Acid Amides; Polyols; Hemiaminals; Tertiary Amines; Azetidines; Secondary Carboxylic Acid Amides; Carboxylic Acids; Enamines; Enolates; Aminals; Polyamines; Thioethers</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; 2,4-disubstituted 1,3-thiazole; dicarboxylic acid derivative; primary aromatic amine; 1,3-thiazolamine; meta-thiazine; thiazole; azole; tertiary carboxylic acid amide; enone; carboxamide group; polyol; tertiary amine; azetidine; secondary carboxylic acid amide; hemiaminal; polyamine; enolate; thioether; enamine; aminal; carboxylic acid derivative; carboxylic acid; primary amine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moeity or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.</td></tr><tr><th>Pharmacodynamics</th><td>Ceftibuten is a third-generation cephalosporin antibiotic.</td></tr><tr><th>Mechanism of action</th><td>Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed following oral administration.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.21 L/kg [adult subjects]</li>
	<li>0.5 L/kg [fasting pediatric patients]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Ceftibuten is 65% bound to plasma proteins. The protein binding is independent of plasma ceftibuten concentration.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>A study with radiolabeled ceftibuten administered to 6 healthy adult male volunteers demonstrated that cis-ceftibuten is the predominant component in both plasma and urine. About 10% of ceftibuten is converted to the trans-isomer is approximately 1/8 as antimicrobially potent as the cis-isomer.</p></td></tr><tr><th>Route of elimination</th><td>Ceftibuten is excreted in the urine; 95% of the administered radioactivity was recovered either in urine or feces.</td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Overdosage of cephalosporins can cause cerebral irritation leading to convulsions. </td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.5755</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9679</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5424</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9274</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9586</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.929</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8531</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8293</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6007</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8787</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8817</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9191</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8833</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9625</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9387</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7274
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8961
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9688
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.6446 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9848
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9305
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pernix therapeutics llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.schering.de">Schering Corp.</a></li>
<li>Sciele Pharma Inc.</li>
<li><a href="http://www.shionogi-inc.com">Shionogi Pharma Inc.</a></li>
<li>Zyber Pharmaceuticals</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Suspension</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>